Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

doi:10.1016/j.cell.2020.09.005

Review

. 2020 Oct 1;183(1):4-10.

doi: 10.1016/j.cell.2020.09.005. Epub 2020 Sep 3.

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Lewis Au¹, Laura Amanda Boos², Anthony Swerdlow³, Fiona Byrne⁴, Scott T C Shepherd¹, Annika Fendler⁴, Samra Turajlic⁵; CAPTURE investigators

Affiliations

¹ Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
² Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
⁴ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
⁵ Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 32979319
PMCID: PMC7470737
DOI: 10.1016/j.cell.2020.09.005

Review

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Lewis Au et al. Cell. 2020.

. 2020 Oct 1;183(1):4-10.

doi: 10.1016/j.cell.2020.09.005. Epub 2020 Sep 3.

Authors

Lewis Au¹, Laura Amanda Boos², Anthony Swerdlow³, Fiona Byrne⁴, Scott T C Shepherd¹, Annika Fendler⁴, Samra Turajlic⁵; CAPTURE investigators

Affiliations

¹ Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
² Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
⁴ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
⁵ Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

PMID: 32979319
PMCID: PMC7470737
DOI: 10.1016/j.cell.2020.09.005

Abstract

The SARS-CoV-2 pandemic has posed a significant challenge for risk evaluation and mitigation among cancer patients. Susceptibility to and severity of COVID-19 in cancer patients has not been studied in a prospective and broadly applicable manner. CAPTURE is a pan-cancer, longitudinal immune profiling study designed to address this knowledge gap.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests S.T. reports grants and speaker fees from Roche Tissue Diagnostics. L.A., L.B., F.B., S.S., A.F., A.S. have no conflicts of interest to declare.

Figures

**Figure 1**
Schematic Representation of Immune Changes in Cancer Patients that Can Impact Immune Response during a SARS-CoV-2 Infection (A) Cancer type, stage, and therapy (including surgery, systemic anti-cancer therapy, and other anti-cancer interventions) can result in varying degrees of immune suppression, which conceivably may lead to increased clinical susceptibility to SARS-CoV-2 infection and COVID-19 illness. (B) Examples of the varied mechanisms by which host immunity (innate or humoral/cellular adaptive immunity) is altered, with potential influence on the immune response as well as immunopathologic hyperinflammation of COVID-19. SACT, systemic anti-cancer therapy; Rx, other anti-cancer treatments including radio-, hormonal, targeted, and cellular therapy; ADT, androgen deprivation therapy; CAR-T, chimeric antigen receptor T cell.

**Figure 2**
Overview of CAPTURE Study Procedures and Analysis Plans Patients are recruited into study arms A or B, and follow-up schedules are bespoke to their COVID-19 status and accounts for their clinical visit/treatment requirements; while healthcare workers are recruited and followed-up according to schedule as outlined. Comprehensive demographic, epidemiological, and clinical data will be collected along with swabs and blood samples. Diagnostic assays will be performed for all participants and will inform selection of samples for detailed immune monitoring and next-generation sequencing. Standard operating procedure documents (for local sample collection, processing, and storage) will be implemented in additional institutions, and sample analyses will be centralized to ensure standardization.

See this image and copyright information in PMC

Cited by

Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy.
Hatic H, Hearld KR, Das D, Deshane J. Hatic H, et al. Cancers (Basel). 2022 Dec 1;14(23):5954. doi: 10.3390/cancers14235954. Cancers (Basel). 2022. PMID: 36497435 Free PMC article.
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Wilkinson KA, Schmitt AM, Tippu Z, Shum B, Farag S, Rogiers A, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Deng D, Kjaer S, Song OR, Queval CJ, Kavanagh C, Wall EC, Carr EJ, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Popat S, Yousaf N, Jhanji S, Tatham K, Cunningham D, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S. Fendler A, et al. Cell Rep Med. 2022 Oct 18;3(10):100781. doi: 10.1016/j.xcrm.2022.100781. Epub 2022 Sep 27. Cell Rep Med. 2022. PMID: 36240755 Free PMC article.
Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M, Aguilar-Gallardo C, Montoro J, Francés-Gómez C, Latorre V, Luna I, Planelles D, Carrasco MP, Gómez MD, González-Barberá EM, Aguado C, Sempere A, Solves P, Gómez-Seguí I, Balaguer-Rosello A, Louro A, Perla A, Larrea L, Sanz J, Arbona C, de la Rubia J, Geller R, Sanz MÁ, Sanz G, Luis Piñana J. Guerreiro M, et al. Transpl Infect Dis. 2021 Aug;23(4):e13602. doi: 10.1111/tid.13602. Epub 2021 Mar 31. Transpl Infect Dis. 2021. PMID: 33728702 Free PMC article.
SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage.
Ma J, Zhu F, Zhao M, Shao F, Yu D, Ma J, Zhang X, Li W, Qian Y, Zhang Y, Jiang D, Wang S, Xia P. Ma J, et al. EMBO J. 2021 Sep 15;40(18):e108249. doi: 10.15252/embj.2021108249. Epub 2021 Aug 4. EMBO J. 2021. PMID: 34296442 Free PMC article.
Systemic therapy and COVID19: Immunotherapy and chemotherapy.
Gulati S, Muddasani R, Gustavo Bergerot P, Pal SK. Gulati S, et al. Urol Oncol. 2021 Apr;39(4):213-220. doi: 10.1016/j.urolonc.2020.12.022. Epub 2020 Dec 26. Urol Oncol. 2021. PMID: 33451934 Free PMC article. Review.

See all "Cited by" articles

References

1. COVIDSurg Collaborative Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27–38. - PMC - PubMed
1. Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791. - PMC - PubMed
1. Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C., et al. TERAVOLT investigators COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. - PMC - PubMed
1. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. - PMC - PubMed
1. Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G., Jr., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] COVIDSurg Collaborative Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27–38. - PMC - PubMed

[2] COVIDSurg Collaborative Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020;396:27–38. - PMC - PubMed

[3] Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791. - PMC - PubMed

[4] Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–791. - PMC - PubMed

[5] Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C., et al. TERAVOLT investigators COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. - PMC - PubMed

[6] Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C., et al. TERAVOLT investigators COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. - PMC - PubMed

[7] Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. - PMC - PubMed

[8] Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. - PMC - PubMed

[9] Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G., Jr., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed

[10] Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G., Jr., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Affiliations

Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous